Blood cancers

VRd for initial treatment of multiple myeloma – Prof Hang Quach discusses the new MSAG recommendations


Australian clinicians now have PBS access to combination bortezomib/lenalidomide/dexamethasone (VRd) for upfront treatment of multiple myeloma.

In this podcast, Professor Hang Quach discusses the key recommendations of the Medical and Scientific Advisory Group (MSAG) update on upfront VRd, and offers insights from her own experiences of its use in the clinic.

Professor Hang Quach Hang is co-author of the MSAG update on VRd for initial treatment of multiple myeloma. She is Director of the Clinical Haematology Service and also Director of the Haematology Clinical Research at St Vincent’s Hospital in Melbourne, and Professor of Haematology at the Melbourne University.

This podcast was created independently by the limbic. Thank you to Bristol Myers Squibb Pty Ltd for providing the non restrictive educational grant that made it possible.

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic